“There are many great medical research institutes that study fundamental questions about cancer, and excellent hospitals that study fundamental questions about cancer and provide wonderful care. But very few medical research institutes manage to achieve the critical mix where scientists, doctors, patients and families collaborate to make an impact on cancer care. This ability to partner and collaborate is what motivates us and drives the research excellence to which everyone at ONJCRI is committed.”

Professor Matthias Ernst (Scientific Director) and Professor Jonathan Cebon (Medical Director), ONJCRI

Cancer and Inflammation Program

The Cancer and Inflammation Program focuses on understanding the molecular mechanisms found in normal cells become coerced and corrupted by cancer cells to support the growth and spread of cancer cells. Identifying and understanding the molecular mechanisms that underpin these processes provides novel therapeutic targets for the treatment of cancer.

This program is lead by Professor Matthias Ernst

Cancer Immunobiology Program

The Cancer Immunobiology program aims to better understand the interactions that occur between cancers and the immune system to harness the power of immune cells to seek out and kill cancer cells. This research also identifies biomarkers and develops assays for their detection in patients to better tailor personalized cancer medicine to individual patients.

This program is lead by Professor Jonathan Cebon

Additional information is available about our Translational Genomics & Epigenomics Laboratory lead by Assistant Professor Alex Dobrovic.

Gastrointestinal Cancers

The Gastrointestinal cancer program investigates the molecular mechanisms that disturb cellular differentiation, proliferation and survival and cause or perpetuate cancer. The research focuses on transcriptional and epigenetic mechanisms, and also aims to discover biomarkers to better tailor therapies to cancer patients.

This program is lead by Professor John Mariadason

Additional information is available about our Cell Death & Survival Laboratory lead by Dr Doug Fairlie.

Translational Breast Cancer Program

The Translational Breast Cancer Program seeks to identify the cancer cells that have the ability to spread to other tissues, a process called metastasis. By recognising these cells, and the genes that they express, new therapies that target these cells and their interactions with normal cells in their microenvironment can be developed to help patients with advanced breast cancer.

This program is lead by Professor Robin Anderson

Additional information is available about our Tumour Progression & Heterogeneity Laboratory lead by Dr Delphine Merino.

And our Matrix Microenvironment & Metastasis Laboratory lead by Dr Normand Pouliot

Tumour Targeting Program

The Tumour Targeting Program aims to identify novel targets for cancer drug development and that are suited for antibody-based therapy and visualisation of cancer cells. Through sophisticated protein engineering and molecular imaging techniques, novel diagnostic and therapeutic approaches to a range of cancers are being developed, and extended into clinical studies in cancer patients.

Centre for Research Excellence in Brain Cancer

The Centre for Research Excellence in Brain Cancer was established through the Victorian Cancer Agency to develop innovative approaches to diagnosing and treating brain cancers, and to take new discoveries into clinical trials in brain cancer patients.

The Centre is co-lead by Professor Andrew Scott and Assistant Professor Hui Gan